ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011
Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning?
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.Targeted oncology · 2015Trial
- How appropriate is treating patients diagnosed with advanced esophageal cancer with anticancer drugs? A multicenter retrospective cohort Spanish study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy.Frontiers in immunology · 2021Review
- Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors.Molecular cancer therapeutics · 2019Article
- Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma.Frontiers in oncology · 2019Review
- Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy.OncoTargets and therapy · 2017Article
- Comparative evaluation of strategies for quantifying signaling pathway proteins in Ewing sarcoma.Applied immunohistochemistry & molecular morphology : AIMM · 2014Article
- Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG.Journal of the National Cancer Institute · 2013Article
- Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients.Targeted oncology · 2013Article
- Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Paediatric drugs · 2013Review
- Targeted therapies for bone sarcomas.BoneKEy reports · 2013Article
- E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis.Cell death & disease · 2013Review
- Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.Frontiers in oncology · 2013Article
- Article
- Article
- Bone sarcomas: from biology to targeted therapies.Sarcoma · 2012Article
- The first European interdisciplinary ewing sarcoma research summit.Frontiers in oncology · 2012Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.